These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 33468477)

  • 1. Semimechanistic Pharmacokinetic and Pharmacodynamic Modeling of Piperaquine in a Volunteer Infection Study with Plasmodium falciparum Blood-Stage Malaria.
    Wattanakul T; Baker M; Mohrle J; McWhinney B; Hoglund RM; McCarthy JS; Tarning J
    Antimicrob Agents Chemother; 2021 Mar; 65(4):. PubMed ID: 33468477
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Dihydroartemisinin-piperaquine failure associated with a triple mutant including kelch13 C580Y in Cambodia: an observational cohort study.
    Spring MD; Lin JT; Manning JE; Vanachayangkul P; Somethy S; Bun R; Se Y; Chann S; Ittiverakul M; Sia-ngam P; Kuntawunginn W; Arsanok M; Buathong N; Chaorattanakawee S; Gosi P; Ta-aksorn W; Chanarat N; Sundrakes S; Kong N; Heng TK; Nou S; Teja-isavadharm P; Pichyangkul S; Phann ST; Balasubramanian S; Juliano JJ; Meshnick SR; Chour CM; Prom S; Lanteri CA; Lon C; Saunders DL
    Lancet Infect Dis; 2015 Jun; 15(6):683-91. PubMed ID: 25877962
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population Pharmacokinetic Properties of Piperaquine in Falciparum Malaria: An Individual Participant Data Meta-Analysis.
    Hoglund RM; Workman L; Edstein MD; Thanh NX; Quang NN; Zongo I; Ouedraogo JB; Borrmann S; Mwai L; Nsanzabana C; Price RN; Dahal P; Sambol NC; Parikh S; Nosten F; Ashley EA; Phyo AP; Lwin KM; McGready R; Day NP; Guerin PJ; White NJ; Barnes KI; Tarning J
    PLoS Med; 2017 Jan; 14(1):e1002212. PubMed ID: 28072872
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety, tolerability, pharmacokinetics, and antimalarial efficacy of a novel Plasmodium falciparum ATP4 inhibitor SJ733: a first-in-human and induced blood-stage malaria phase 1a/b trial.
    Gaur AH; McCarthy JS; Panetta JC; Dallas RH; Woodford J; Tang L; Smith AM; Stewart TB; Branum KC; Freeman BB; Patel ND; John E; Chalon S; Ost S; Heine RN; Richardson JL; Christensen R; Flynn PM; Van Gessel Y; Mitasev B; Möhrle JJ; Gusovsky F; Bebrevska L; Guy RK
    Lancet Infect Dis; 2020 Aug; 20(8):964-975. PubMed ID: 32275867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predicting the parasite killing effect of artemisinin combination therapy in a murine malaria model.
    Patel K; Batty KT; Moore BR; Gibbons PL; Kirkpatrick CM
    J Antimicrob Chemother; 2014 Aug; 69(8):2155-63. PubMed ID: 24777899
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dihydroartemisinin-piperaquine against multidrug-resistant Plasmodium falciparum malaria in Vietnam: randomised clinical trial.
    Tran TH; Dolecek C; Pham PM; Nguyen TD; Nguyen TT; Le HT; Dong TH; Tran TT; Stepniewska K; White NJ; Farrar J
    Lancet; 2004 Jan; 363(9402):18-22. PubMed ID: 14723988
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b/4 trial.
    West African Network for Clinical Trials of Antimalarial Drugs (WANECAM)
    Lancet; 2018 Apr; 391(10128):1378-1390. PubMed ID: 29606364
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Defining the Antimalarial Activity of Cipargamin in Healthy Volunteers Experimentally Infected with Blood-Stage Plasmodium falciparum.
    McCarthy JS; Abd-Rahman AN; Collins KA; Marquart L; Griffin P; Kümmel A; Fuchs A; Winnips C; Mishra V; Csermak-Renner K; Jain JP; Gandhi P
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33199389
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Piperaquine Pharmacokinetics during Intermittent Preventive Treatment for Malaria in Pregnancy.
    Chotsiri P; Gutman JR; Ahmed R; Poespoprodjo JR; Syafruddin D; Khairallah C; Asih PBS; L'lanziva A; Otieno K; Kariuki S; Ouma P; Were V; Katana A; Price RN; Desai M; Ter Kuile FO; Tarning J
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33361303
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Susceptibility of Plasmodium falciparum to artemisinins and Plasmodium vivax to chloroquine in Phuoc Chien Commune, Ninh Thuan Province, south-central Vietnam.
    Phong NC; Chavchich M; Quang HH; San NN; Birrell GW; Chuang I; Martin NJ; Manh ND; Edstein MD
    Malar J; 2019 Jan; 18(1):10. PubMed ID: 30654808
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and parasite clearance of artemisinin-resistant Plasmodium falciparum infection: A pilot and a randomised volunteer infection study in Australia.
    Watts RE; Odedra A; Marquart L; Webb L; Abd-Rahman AN; Cascales L; Chalon S; Rebelo M; Pava Z; Collins KA; Pasay C; Chen N; Peatey CL; Möhrle JJ; McCarthy JS
    PLoS Med; 2020 Aug; 17(8):e1003203. PubMed ID: 32822347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A surrogate marker of piperaquine-resistant Plasmodium falciparum malaria: a phenotype-genotype association study.
    Witkowski B; Duru V; Khim N; Ross LS; Saintpierre B; Beghain J; Chy S; Kim S; Ke S; Kloeung N; Eam R; Khean C; Ken M; Loch K; Bouillon A; Domergue A; Ma L; Bouchier C; Leang R; Huy R; Nuel G; Barale JC; Legrand E; Ringwald P; Fidock DA; Mercereau-Puijalon O; Ariey F; Ménard D
    Lancet Infect Dis; 2017 Feb; 17(2):174-183. PubMed ID: 27818097
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Piperaquine concentration and malaria treatment outcomes in Ugandan children treated for severe malaria with intravenous Artesunate or quinine plus Dihydroartemisinin-Piperaquine.
    Byakika-Kibwika P; Ssenyonga R; Lamorde M; Blessborn D; Tarning J
    BMC Infect Dis; 2019 Dec; 19(1):1025. PubMed ID: 31795967
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Safety, pharmacokinetics, and antimalarial activity of the novel plasmodium eukaryotic translation elongation factor 2 inhibitor M5717: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study and volunteer infection study.
    McCarthy JS; Yalkinoglu Ö; Odedra A; Webster R; Oeuvray C; Tappert A; Bezuidenhout D; Giddins MJ; Dhingra SK; Fidock DA; Marquart L; Webb L; Yin X; Khandelwal A; Bagchus WM
    Lancet Infect Dis; 2021 Dec; 21(12):1713-1724. PubMed ID: 34715032
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A trial of combination antimalarial therapies in children from Papua New Guinea.
    Karunajeewa HA; Mueller I; Senn M; Lin E; Law I; Gomorrai PS; Oa O; Griffin S; Kotab K; Suano P; Tarongka N; Ura A; Lautu D; Page-Sharp M; Wong R; Salman S; Siba P; Ilett KF; Davis TM
    N Engl J Med; 2008 Dec; 359(24):2545-57. PubMed ID: 19064624
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Population pharmacokinetic and pharmacodynamic properties of artesunate in patients with artemisinin sensitive and resistant infections in Southern Myanmar.
    Lohy Das JP; Kyaw MP; Nyunt MH; Chit K; Aye KH; Aye MM; Karlsson MO; Bergstrand M; Tarning J
    Malar J; 2018 Mar; 17(1):126. PubMed ID: 29566683
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized, double-blind, placebo-controlled clinical trial of a two-day regimen of dihydroartemisinin-piperaquine for malaria prevention halted for concern over prolonged corrected QT interval.
    Manning J; Vanachayangkul P; Lon C; Spring M; So M; Sea D; Se Y; Somethy S; Phann ST; Chann S; Sriwichai S; Buathong N; Kuntawunginn W; Mitprasat M; Siripokasupkul R; Teja-Isavadharm P; Soh E; Timmermans A; Lanteri C; Kaewkungwal J; Auayporn M; Tang D; Chour CM; Prom S; Haigney M; Cantilena L; Saunders D
    Antimicrob Agents Chemother; 2014 Oct; 58(10):6056-67. PubMed ID: 25092702
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of dihydroartemisinin/piperaquine and artesunate monotherapy for the treatment of uncomplicated Plasmodium falciparum malaria in Central Vietnam.
    Rovira-Vallbona E; Van Hong N; Kattenberg JH; Huan RM; Hien NTT; Ngoc NTH; Guetens P; Hieu NL; Mai TT; Duong NTT; Duong TT; Phuc BQ; Xa NX; Erhart A; Rosanas-Urgell A
    J Antimicrob Chemother; 2020 Aug; 75(8):2272-2281. PubMed ID: 32437557
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety, pharmacokinetics, and antimalarial activity of the novel triaminopyrimidine ZY-19489: a first-in-human, randomised, placebo-controlled, double-blind, single ascending dose study, pilot food-effect study, and volunteer infection study.
    Barber BE; Fernandez M; Patel HB; Barcelo C; Woolley SD; Patel H; Llewellyn S; Abd-Rahman AN; Sharma S; Jain M; Ghoghari A; Di Resta I; Fuchs A; Deni I; Yeo T; Mok S; Fidock DA; Chalon S; Möhrle JJ; Parmar D; McCarthy JS; Kansagra K
    Lancet Infect Dis; 2022 Jun; 22(6):879-890. PubMed ID: 35247321
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A population pharmacokinetic model of piperaquine in pregnant and non-pregnant women with uncomplicated Plasmodium falciparum malaria in Sudan.
    Hoglund RM; Adam I; Hanpithakpong W; Ashton M; Lindegardh N; Day NP; White NJ; Nosten F; Tarning J
    Malar J; 2012 Nov; 11():398. PubMed ID: 23190801
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.